ArticleInterdisciplinary sciences, computational life sciences2024
Machine Learning Accelerates De Novo Design of Antimicrobial Peptides.
Article in Interdisciplinary sciences, computational life sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Natural and Synthetic AMPs from Latin America across Diversity Engineering and Applications.ACS infectious diseases · 2026Review
- DeepACPred: an integrated multistage framework for anticancer peptide discovery and activity prediction.Briefings in bioinformatics · 2026Article
- Integrative computational-experimental discovery and translation of antifungal peptides for multidrug-resistant fungi.Frontiers in microbiology · 2026Review
- Current Advances in Developing New Antimicrobial Agents Against Non-TuberculousAntibiotics (Basel, Switzerland) · 2025Review
- Progress in the Identification and Design of Novel Antimicrobial Peptides Against Pathogenic Microorganisms.Probiotics and antimicrobial proteins · 2025Review
- Deep Learning Combined with Quantitative Structure‒Activity Relationship Accelerates De Novo Design of Antifungal Peptides.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Multi-Objective Optimization Accelerates the De Novo Design of Antimicrobial Peptide forInternational journal of molecular sciences · 2024Article
- PADG-Pred: Exploring Ensemble Approaches for Identifying Parkinson's Disease Associated Biomarkers Using Genomic Sequences Analysis.IET systems biologyArticle
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
Efficient and precise design of antimicrobial peptides (AMPs) is of great importance in the field of AMP development. Computing provides opportunities for peptide de novo design. In the present investigation, a new machine learning-based AMP prediction model, AP_Sin, was trained using 1160 AMP sequences and 1160 non-AMP sequences. The results showed that AP_Sin correctly classified 94.61% of AMPs on a comprehensive dataset, outperforming the mainstream and open-source models (Antimicrobial Peptide Scanner vr.2, iAMPpred and AMPlify) and being effective in identifying AMPs. In addition, a peptide sequence generator, AP_Gen, was devised based on the concept of recombining dominant amino acids and dipeptide compositions. After inputting the parameters of the 71 tridecapeptides from antimicrobial peptides database (APD3) into AP_Gen, a tridecapeptide bank consisting of de novo designed 17,496 tridecapeptide sequences were randomly generated, from which 2675 candidate AMP sequences were identified by AP_Sin. Chemical synthesis was performed on 180 randomly selected candidate AMP sequences, of which 18 showed high antimicrobial activities against a wide range of the tested pathogenic microorganisms, and 16 of which had a minimal inhibitory concentration of less than 10 μg/mL against at least one of the tested pathogenic microorganisms. The method established in this research accelerates the discovery of valuable candidate AMPs and provides a novel approach for de novo design of antimicrobial peptides.
Indexed as
Identifiers
38416364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.